• Presented at World Conference on Lung Cancer (2022)

  • Collaborator: Novartis

  • Authors: Pauline Frank, Andrew Ciupek, Pasquale Varriale, Julie Laurent, Ortal Bar Ziv

Lung cancer is the second most common malignancy that affects men and women and it
is the leading cause of cancer related deaths. Globally in 2020, there were ~2 million new cases of
lung cancer and ~1.8 million deaths. Approximately 10-15% of lung cancer cases are classified as
small cell lung cancer (SCLC) while the majority of all cases (80-85%) are classified as non-small cell
lung cancer (NSCLC). Factors commonly considered (among others) in the determination of NSCLC
prognosis include age, performance status, weight loss, and tumor-node-metastasis staging. The
5-year overall survival rate of people living with lung cancer is up to ~90% for those diagnosed with
early-stage vs ~63% with localized and ~7% with metastatic disease.

Objective: There is growing evidence that experiences and outcomes of people with lung cancer are
impacted not only by treatments, but also by quality of clinical care and supportive resources. For a
better understanding of the care pathway differences in people living with cancer and their unmet
support needs, we conducted a global survey of people with lung cancer.